Clinical Trial Update: Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) [Phase 1]

View source ↗

Summary

The document reports the completion of a Phase 1 study evaluating the combination of sorafenib and BIIB022 in hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BIIB022
• Nexavar (Sorafenib)

Snippet

Sponsor: Biogen | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED